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benefit to brachytherapy in a boost situation, and in retreating 
recurrent cancer where it may be necessary to restrict reirradiation of 
critical structures that received significant dose in the first 
treatment. 
Though permanent I125 seed implants have been successful in 
delivering low-dose-rate brachytherapy to prostate, most 
brachytherapy now uses high dose-rate plans from Ir192 which have 
the advantage that more precise dosing is obtained by modern remote 
afterloading systems which can vary dwell times at each position of 
the source. Radiobiologically, high dose-rate delivery is also 
advantageous in sparing late-reacting normal tissue where repair is 
usually slower than in the malignancy, though this biological 
advantage does require high dose-rate brachytherapy to be 
fractionated. 
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Introduction: In breast cancer, the target volume for a boost to the 
high risk area of residual disease is the primary tumour bed including 
the surrounding breast tissue. Especially in Europe, the use of 
brachytherapy (BT) as a boost modality is gradually being replaced by 
3D-CRT photon beam techniques because of logistic reasons. However, 
multi-catheter interstitial BT remains popular, especially for APBI, and 
is being investigated for treatment of recurrences/new primaries in 
the same breast.  
Technical aspects: Especially tumours located centrally or peripheral 
in the breast are suited for treatment with BT. Rigid or flexible 
afterloading catheters are placed under anaesthesia in the breast 
tissue around the lumpectomy cavity. The number of catheters 
depend on the size and shape of the target, in agreement with BT 
guidelines. Most often 5-9 catheters are positioned at 1-2 cm distance 
in 1-3 planes to ensure adequate coverage and a homogeneous dose. 
The lumpectomy cavity can be identified by pre-operative imaging, 
palpation, per-operative ultrasound or radio-opaque clips positioned 
during surgery. A template is used to properly position the catheters. 
A planning-CT scan for dosimetry is made the day after the 
implantation to allow resolution of swelling. The CTV is delineated as 
the lumpectomy cavity with a margin in all directions (often 1-1.5 cm) 
in the breast tissue, thereby excluding the skin (at least 5 mm) and 
pectoral muscles. Currently, a PDR (15-20 pulses of 1 Gy) or HDR (7 
Gy) 192Ir after-loader is mostly used. 3D-TPS dwell-time optimisation is 
used based on the CTV taking into account the implant geometry.   
Results: In the EORTC “boost-trial”1, a total of 2661 patients received 
a boost dose of 16 Gy after complete tumour resection. The boost 
technique was: 63% direct electron field, 28% photon beams and 9% 
interstitial BT. The 10-year cumulative incidence of local relapse was 
6.3% for electrons (95% CI. 5.1-7.5%), 5.3% for photons (95% C.I. 3.6-
7.0%) and 3.7% for BT (95% C.I. 1.2-6.2%) (p = 0.13). The occurrence of 
(any grade of) fibrosis was similar in the 3 groups: 70%, 66% and 72%, 
respectively. Harms2 treated 113 patients with risk factors for local 
control (close or positive margins, vascular invasion, T2G3) with an 
interstitial PDR boost of 15-25 pulses of 1 Gy.  At 5 years, the 
actuarial local recurrence-free survival rate was 95%.  Grade 3 skin or 
soft tissue toxicity developed in 10.8% of patients treated with a boost 
of  ≤20 Gy and 54.6% of patients treated with >20 Gy (p < 0.01).  
Cosmetic outcome was scored as excellent or good in 90% by patient 
assessment, and in 80% by physician assessment. Niehoff3 found no 
difference in the outcome between interstitial HDR or PDR BT in re-
irradiation for breast or chest wall recurrences of 32 patients.   
Advantages and challenges: As with BT the implant moves together 
with the lumpectomy cavity, no supplementary margin is required to 
obtain the PTV.  Moreover, the shape and size of the surgical cavity is 
less important as irregularly shaped cavities can be conformally 
treated using modern treatment planning techniques. Oncoplastic 
resection and reconstruction techniques offer a challenge for proper 
localisation of the CTV, with BT offering the advantage of the ability 
to shape the treated volume based on imaging and marker clips 
positioned around the primary tumour bed. As anaesthesia is required 
for the implant procedure, a challenge remains to either perform it 
under local anaesthesia or to per-operatively combine it with tumour 
resection. Delivering BT according to current standards requires 
specialised training and experience of a team consisting of radiation 
oncologists, medical physicists and radiation technologists.  
Conclusions: The brachytherapy technique has several advantages and 
therefore will continue to be used, especially for APBI. In addition, an 
appealing new feature lies in its use as secondary breast conserving 
treatment. 
1 Poortmans P et al. Radiother Oncol. 2004;72:25-33. 
2 Harms W et al. Strahlenther Onkol 2002;178:607-614. 
3 Niehoff P et al. Strahlenther Onkol 2006;182:102-107. 
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High-dose-rate (HDR) brachytherapy is an established curative 
treatment option for patients diagnosed with prostate cancer. Several 
advantages of HDR brachytherapy over other radiotherapy techniques 
have been identified: (1) the accurate positioning of the sources by 
first implanting non-active guide needles, (2) the possibility to exactly 
choose the position of the source over the entire length of every 
single needle, (3) the absence of any target movement during 
irradiation, (4) the possibility of “on line” adjustments of dwell source 
locations  according to 3D planning based on individual dose 
prescription, (5) the absence of any need for pre-implant needles 
preparation, and finally (6) a safer radio-protection profile as 
compared to permanent seeds implant procedure. 
The greatest clinical experience with HDR for prostate cancer involves 
its combination with EBRT. A systematic review of available literature 
has compared EBRT alone (at doses > 75 Gy), EBRT combined with 
HDR brachytherapy boost and EBRT combined with LDR permanent 
seeds boost in terms of efficacy endpoints. Despite the fact that 
patients treated with EBRT+HDR boost had more advanced disease, 
both biochemical disease free survival (biochemical Not Evidence of 
Disease, bNED) and overall survival rates were significantly better 
with this combination. Moreover the results of the only phase III 
randomized trial available in this field comparing EBRT alone (55 Gy in 
20 fractions) versus a combined EBRT (35,75 Gy in 13 fractions) + a 
HDR boost of 2 fractions of 8,5 Gy showed a significant advantage in 
bNED favoring the combined arm.  
Acute toxicity consists of mild LUTS (dysuria, urinary frequency, 
urgency) in 40 to 60% of patients but grade 3 genito-urinary (GU) 
symptoms are only presents in 1-5%. The return to base-line values is 
obtained much earlier than after LDR brachytherapy. In the 
immediate post-implant hours, hematuria is also relatively common 
but resolves rapidly . Urethral stricture is the most frequent non-
trivial late toxicity reported occurring in the bulbo-membranous 
urethra in more than 90% of the cases. Overall, it develops in 5 to 15% 
of patients with patient-related predictors being identified such as a 
prior history of TURP, an elevated pre-implant IPS-Score, older age, 
prostate volume (and use of neo-adjuvant ADT for pre-implant 
downsizing) and hypertension but also with a number of treatment-
related ones (HDR dose per fraction, number of midlines needles 
implanted, a long Z-axis of the CTV). Incontinence is less common and 
typically related to post-implant need of a TURP. Gastro-intestinal 
(GI) toxicity is frequently dependent on EBRT protocol adopted 
(irradiated volumes, prostate alone versus pelvis ± prostate CTV, 
dose/fraction to the pelvis) with grade 3 toxicity reported 
occasionally and proctitis, anal pain and rectal bleeding occurring in 
less than 5% of patients in all published papers.  
Several areas remain for further investigations and should be explored 
in future trials. (1) The optimal dosing regimens is still unclear: the 
first published series adopted  HDR schedules of two or more fractions 
while recently protocols proposing a single fraction/implant  have 
been developed with encouraging early results thus minimizing the 
risk of potential needles/catheters displacement between fractions. 
(2) HDR brachytherapy has been proposed for local salvage after 
biopsy proven intraprostatic relapse of irradiated prostate cancers 
with encouraging results but larger series with longer follow-up are 
needed to fully validate this strategy . (3) The typical inhomogeneous 
dose distribution obtained with brachytherapy techniques can be 
exploited in view of a “focal irradiation” of the prostate for carefully 
selected patients harboring limited unilateral cancers. (4) Costs of 
temporary HDR brachytherapy are limited. Rigorous cost-analysis and 
comparisons between therapeutic alternatives have so far never been 
attempted but if HDR brachytherapy techniques are able to 
convincingly demonstrate a cost-effective advantage as compared to 
other therapeutic options for localized prostate cancer, the procedure 
is likely to be offered in the near future to increasing numbers of 
patients.  
 
SP-0122   
Brachytherapy boost with complementary external beam 
irradiation in anal canal cancer 
G. Kovács1 
1Universität Lübeck, Interdisciplinary Brachytherapy Unit, Lübeck, 
Germany  
  
Introduction: Primary radiotherapy in form of external beam 
radiotherapy (EBRT) combined withchemotherapy or combined with 
local dose escalation by brachytherapy enables anal sphincter 
